Substituted Amide Derivatives for Multimodal Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly opioids, are limited by their efficacy and side effects, and there is a need for alternative compounds that can effectively target both the µ-opioid receptor and sigma-1 receptor to address chronic and neuropathic pain without adverse events.
Innovation Solution
Development of structurally distinct substituted amide derivatives that act as dual ligands binding to both the µ-opioid receptor and sigma-1 receptor, offering a multimodal analgesic approach to enhance opioid analgesia while reducing side effects through synergistic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MOR agonists are administered to treat pain, then analgesic efficacy is improved, but side effects such as constipation, respiratory depression, tolerance, emesis and physical dependence worsen
Solution Approach 1:
The patent combines two distinct pharmacological mechanisms into a single compound: μ-opioid receptor agonism for analgesia and sigma-1 receptor antagonism to reduce side effects. This merging of functions allows the compound to provide effective pain relief while simultaneously mitigating the harmful effects associated with traditional opioid therapy
Solution Approach 2:
The dual-action compound serves multiple therapeutic functions simultaneously: it acts as an analgesic through MOR activation, while also functioning as a side-effect mitigator through σ1R antagonism. This multi-functionality addresses both the primary indication (pain) and the secondary problems (side effects) with a single agent
2Duration of action of moving object
If MOR agonists are used for chronic pain treatment, then acute pain relief is achieved, but effectiveness diminishes due to MOR down-regulation and tolerance
Solution Approach 1:
The σ1R antagonistic component acts in advance to prevent the development of tolerance and down-regulation that typically occur with chronic MOR agonist use. By blocking sigma-1 receptors, the compound preemptively counteracts the adaptive changes that would otherwise reduce analgesic effectiveness over time
Solution Approach 2:
The compound combines MOR agonism for sustained analgesia with σ1R antagonism to prevent tolerance development, enabling long-term chronic pain management without the diminishing effectiveness seen with traditional opioids
3Reliability
If increased dosing is used to maintain pain relief, then analgesic efficacy is maintained, but side effects become unacceptable
Solution Approach 1:
The dual-action mechanism allows maintenance of effective analgesia at lower doses by combining MOR agonism with σ1R antagonism, avoiding the need to increase dosing and thereby preventing the escalation of side effects that occurs with traditional opioid therapy
Data Source
AI summary
The present invention relates to substituted amide derivatives of formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the p-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.